GSK's Bepirovirsen Receives US FDA Priority Review & Breakthrough Therapy Designation for Chronic Hepatitis B

summarizeSummary

GSK announced that the US FDA has accepted bepirovirsen for priority review and granted it Breakthrough Therapy Designation for chronic hepatitis B, setting a PDUFA date of October 26, 2026.

check_boxKey Events

• US FDA Accepts Bepirovirsen for Priority Review

  The New Drug Application (NDA) for bepirovirsen, an investigational antisense oligonucleotide for chronic hepatitis B, has been accepted for priority review by the US FDA, accelerating its potential market entry.

• Granted Breakthrough Therapy Designation

  Bepirovirsen received Breakthrough Therapy Designation (BTD), indicating preliminary clinical evidence suggests substantial improvement over available therapies for chronic hepatitis B. This builds on a prior Fast Track Designation.

• PDUFA Date Set

  The FDA has assigned October 26, 2026, as the Prescription Drug User Fee Act (PDUFA) goal date for a decision on bepirovirsen.

• Addresses Significant Unmet Medical Need

  The regulatory submission is supported by positive Phase III B-Well trials, demonstrating clinically meaningful functional cure rates for chronic hepatitis B, a global health challenge affecting over 250 million people with limited treatment options.

auto_awesomeAnalysis

The US FDA's acceptance of bepirovirsen for priority review, coupled with Breakthrough Therapy Designation, significantly de-risks the drug's path to market. This dual recognition underscores the FDA's view of bepirovirsen's potential to offer substantial improvement over existing treatments for chronic hepatitis B, a condition affecting over 250 million people globally with low current cure rates. The assigned PDUFA date provides a clear timeline for a regulatory decision, making this a critical milestone for GSK's pipeline and future revenue potential.